· CAR-NK-exosomes demonstrated strong in vitro tumor-killing activity in TNBC cells
· Over 90% of TNBC cells were killed within 10 hours of treatment by CAR-NK-exosomes
· These results validate INOVIQ’s CAR-NK-exosome technology at Peter Mac, a leading cancer research institute
· Studies to evaluate the in vivo tumour-killing activity of CAR-NK-exosomes in a TNBC mouse model will be reported in Q4 CY2025
INOVIQ Limited (ASX: IIQ) (INOVIQ or the Company) is pleased to announce positive results from in vitro validation studies of its CAR-NK-exosome therapeutic candidate at the Peter MacCallum Cancer Centre (Peter Mac). The study confirmed the potent anti-tumour activity of INOVIQ’s proprietary CAR-NK-exosomes in Triple Negative Breast Cancer (TNBC) cells, an aggressive and difficult-to-treat cancer.
The in vitro efficacy of INOVIQ’s CAR-NK-exosomes, derived from human CAR-NK cells, was evaluated in cultured TNBC (Hs578T) cells. The results showed rapid and sustained tumour cell killing in vitro, with over 90% of TNBC cells eliminated within 10 hours of treatment (Abstract| Figure 1 - see attachment). In contrast, control groups, including untreated cells and those treated with non-CAR-NK exosomes, showed minimal tumour cell death. These findings highlight the potent tumour-killing activity of INOVIQ’s CAR-NK-exosomes to target and destroy solid tumours.
Professor Phillip K Darcy PhD FAHMS, Co-leader of the Cancer Immunology program and Group Leader of the Cancer Immunotherapy Laboratory at the Peter Mac and an INOVIQ Medical and Scientific Advisory Board member said: “My team has successfully validated the in vitro tumour-killing activity of INOVIQ’s CAR-NK-exosomes against TNBC cells. CAR-exosomes represent a next-generation, cell-free therapeutic with potential safety and efficacy advantages over autologous cell therapies for the treatment of solid tumours. We are excited by the opportunity to collaborate with INOVIQ to evaluate the therapeutic effect of CAR-NK-EVs in our well-established animal models.”
CEO Dr Leearne Hinch said: “Based on these promising in vitro results, INOVIQ will now progress to in vivo studies to evaluate the efficacy of our CAR-NK-exosomes in animal models of TNBC. Successful completion of these initial preclinical studies will enable us to advance the development of CAR-NK-exosome therapy to IND-enabling studies and further clinical development. We are shaping the future of cancer care, targeting solid tumours with innovative cell-free therapies.”
Authorised for release by Company Secretary, Mark Edwards.
About us:
INOVIQ Ltd (ASX: IIQ) is a leader in exosome technology advancing next-generation diagnostics and therapeutics to transform cancer care. Our product portfolio includes commercial-stage exosome isolation products, clinical-stage diagnostics for ovarian and breast cancer detection, and a preclinical CAR-exosome therapeutic program for solid tumours. INOVIQ is shaping the future of cancer detection and treatment to improve patient outcomes. For more information, visit www.inoviq.com.
Contact details:
Dr Leearne Hinch
Chief Executive Officer
M +61 400 414 416